News Therapies Emerge to Combat Aggressive Lymphomas
Sameer Desai, MD, discusses the changing treatment landscape for lymphomas.
Sameer Desai, MD, medical oncologist/hematologist, Regional Cancer Care Associates, discusses the changing treatment landscape for lymphomas.
In the field, molecular testing has helped to identify which lymphomas are aggressive and which are not. This has led to a slight shift from the standard treatment, Rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP), to new therapies. Further research is underway to determine which therapies are appropriate for each type of lymphoma.
In the second- and third-line settings, CAR T cells are the most exciting addition to the treatment landscape. Currently, the main focus of CAR T cells is limiting severe toxicity. Many patients who received with CAR T-cell therapy experience neurotoxicity and other events. The CAR T-cell agents that are currently being developed will likely be less toxic.
<< View more from the 24th Annual International Congress on Hematologic Malignancies
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
